*Vitreous Retina Macula Consultants of New York, New York, New York; and
†New England Retina Consultants, Springfield, Massachusetts.
Reprint requests: Richard F. Spaide, MD, Vitreous Retina Macula Consultants of New York, 950 Third Avenue, New York, NY 10023; e-mail: [email protected]
R. F. Spaide, received personal compensation from Topcon Medical Systems, Regeneron, Roche, Genentech, Heidelberg Engineering, Adverum Biotechnologies, and DORC. D. R. Lally, received scientific advisory fees from Alimera Sciences, Allergan, Apellis, EyePoint Pharmaceuticals, Genentech, IVERIC Bio, and Novartis as well as research funding from Aldeyra Therapeutics, Annexon Biosciences, Apellis, Chengdu Kanghong, Emmes/MacTel Project, EyePoint Pharmaceuticals, IVERIC Bio, Kodiak Sciences, Novartis, Neurotech, Notal Vision, Optos, and Stealth BioTherapeutics. The work was supported by The Macula Foundation, New York, NY.
None of the authors have any conflicting interests to disclose.